India Pharmas Urge New Government To Take Pro-Pharma Stance
This article was originally published in PharmAsia News
Executive SummaryIndian pharmaceuticals urge the new government to ease up on pricing restrictions and take actions to encourage more industry spending on research and development. Several Indian pharma executives echoed the sentiment that a new government would be favorable to the industry and offered suggestions for reform, greater spending on healthcare and a greater recognition that pharmas need to be seen as part of a growth industry. One executive said the new government should drop proposals to add drugs to be covered under the country's price-control program. (Click here for more
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.